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Polychlorinated biphenyls (PCBs) are persis-
tent pollutants that are ubiquitous in the food
chain, and detectable amounts are in the blood
of almost every person in most populations
that have been examined. Extensive evidence
from animal studies (1) shows that PCBs are
neurotoxins, even at low doses (2), and several
plausible biologic mechanisms of action have
been identified (3,4). Human exposure in
utero to high levels of heat-degraded PCBs is
almost certainly neurotoxic (5).
Whether prenatal and infant exposure to
background levels of PCBs is detrimental for
human neurodevelopment has been under
investigation for nearly 20 years (6).
Statistically significant associations were
found between PCB exposure and child neu-
rodevelopment and cognition in some studies
(7–11) but not others (12–14). The variation
in results across studies could be caused by
any number of factors. For example, a) favor-
able aspects of the early child-care setting
could protect some groups against ill effects
of PCBs; b) a high rate of exposure for a lim-
ited time could be more toxic than chronic
low-level exposure even though both result in
equivalent PCB levels; c) differences existed
in the neurodevelopmental testing protocols;
d) the composition of the PCB mixture in
subjects could have varied across studies; or e)
the association with PCBs was confounded or
modified by concurrent exposures (e.g.,
methylmercury, omega-3 fatty acids) in a
manner that varied across studies and these
exposures were not assessed consistently
across studies. But foremost among the possi-
ble explanations for the variation in findings
across studies is that the degree of PCB
exposure differed. This possibility, however,
has been difficult to assess because methods of
measuring and reporting PCB exposure have
differed. Interpretation of data on PCBs and
neurodevelopment would be more straightfor-
ward if levels of exposure were similarly or
identically quantified. The present report is
devoted entirely to an analysis of the relative
levels of exposure in all studies of background-
level PCB exposure and neurodevelopment.
The variation in reported PCB levels across
studies stems partly from real differences in
exposure levels across populations and calendar
time, but there were also differences in type of
specimen analyzed, sample extraction, chro-
matography, method of quantification, and
data handling and presentation (6).
Sometimes the contribution of measure-
ment techniques to the variation in PCB expo-
sures reported across studies can be assessed by
either sending each laboratory an aliquot from
one large pool or by having material from each
study analyzed at one central laboratory.
Neither of these strategies, however, was an
option for evaluating relative exposure across
the entire group of studies on PCBs and neu-
rodevelopment. Some of the laboratories or
methods used to analyze the specimens are no
longer operational. Furthermore, biologic
specimens were no longer available from all
studies. Because a direct laboratory-based com-
parison of exposure levels across all studies
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Polychlorinated biphenyls (PCBs) are persistent pollutants that are ubiquitous in the food chain,
and detectable amounts are in the blood of almost every person in most populations that have
been examined. Extensive evidence from animal studies shows that PCBs are neurotoxins, even at
low doses. Interpretation of human data regarding low-level, early-life PCB exposure and subse-
quent neurodevelopment is problematic because levels of exposure were not similarly quantified
across studies. We expressed the exposure levels from 10 studies of PCB and neurodevelopment in
a uniform manner using a combination of data from original investigators, laboratory reanalyses,
calculations based on published data, and expert opinion. The mainstay of our comparison was
the median level of PCB 153 in maternal pregnancy serum. The median concentration of PCB
153 in the 10 studies ranged from 30 to 450 ng/g serum lipid, and the median of the 10 medians
was 110 ng/g. We found that a) the distribution of PCB 153 exposure in most studies overlapped
substantially, b) exposure levels in the Faroe Islands study were about 3–4-fold higher than in
most other studies, and c) the exposure levels in the two recent U.S. studies were about one-third
of those in the four earlier U.S. studies or recent Dutch, German, and northern Québec studies.
Our results will facilitate a direct comparison of the findings on PCBs and neurodevelopment
when they are published for all 10 studies. Key words: child development, environmental exposure,
environmental pollutants, neurotoxins, polychlorinated biphenyls. Environ Health Perspect
111:65–70 (2003). [Online 2 December 2002]
doi:10.1289/ehp.5463 available via http://dx.doi.org/
was not possible, we expressed the PCB levels
from studies of neurodevelopment in a uni-
form manner using a combination of data
from original investigators, laboratory reanaly-
ses, calculations based on published data, and
expert opinion. We then compared the PCB
levels across studies and assessed the extent to
which true or technical differences accounted
for the variation. Despite the potential draw-
backs of our approach, it had the advantage of
feasibility, and, we believe, it provided a rea-
sonable indication of the relative exposure lev-
els in the various studies considered.
Methods
Investigators from each study of PCBs and
neurodevelopment of which we were aware
(Table 1) contributed to this study and agreed
on a protocol for parallel presentation of data.
The subjects were from North America, the
European continent, and the Faroe Islands,
located in the Atlantic Ocean northeast of
Scotland. The samples had been collected over
a span of about 40 years. The northern
Québec and Faroe Island populations are
from cultures that consume large amounts of
marine foods. The Michigan and New York
subjects included more freshwater fish eaters
than the general U.S. population has.
The type of specimen originally selected
for analysis varied across laboratories such that
no single specimen type was analyzed in all
studies (Table 1). We therefore chose to use
data for maternal serum (or plasma) where
possible and, when not possible, to use data
for maternal milk levels. For those studies
where we used data for maternal milk, we
reexpressed the levels as maternal serum levels,
using a conversion factor described below. We
chose to express all levels as if they were in
serum so that they could be easily compared
with those in populations for whom measures
in breast milk were not feasible (e.g., men).
For the specimen type specified for each
study (Table 1), we began with the 5th, 25th,
50th, 75th, and 95th percentiles of the distrib-
utions of PCB 153 concentration, and the ratio
of median PCB 118 and median PCB 153
concentrations. PCBs 118 and 153 are desig-
nated by their IUPAC (International Union of
Pure and Applied Chemistry) numbers (19).
The mainstay of our comparison was the
median level of PCB 153 across studies. We
adopted this approach because a) comparison
of the level of a specific congener instead of the
level of the sum of quantitated PCBs was free
from comparability issues caused by quantita-
tion of differing numbers of congeners (Table
2); b) quantitation of PCB 153 levels is rela-
tively straightforward because it is always
among the PCB congeners present at the
highest concentration; c) coelution by other
congeners, if any, is relatively minor; and d)
PCB 153 constitutes a large portion of the
sum of quantitated PCBs in all studies. The
correlations between the concentration of
PCB 153 and the sum of quantitated PCBs
reported have been high: 0.96 (20), 0.89
(21), and 0.97 (22).
We compiled information about labora-
tory methods and method of data handling,
supplementing published material, so that
detailed information was available for each
study (Table 2). The number of specific con-
geners quantitated varied, with the maximum
being 68. Most of the studies providing PCB
measures in milk used a gravimetric proce-
dure to assay lipids.
Methods used in reexpression of results. As
noted above, the data on PCB levels available
to us were not all directly comparable. Thus,
in several cases, we had to reexpress the data.
The methods used to estimate conversion fac-
tors are described here.
Two studies on PCBs and neurodevelop-
ment (7,8) were done when packed column
gas chromatography analyses were standard.
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Table 1. Characteristics of the studies on PCBs and neurodevelopment.
Type of specimena
Reference Location of Years specimens Maternal Maternal Cord Specimen used in Number of
number population collected serum, plasma milk serum the present study specimensb
(15)c U.S./11 cities 1959–1965 + – – Maternal serum 2,737
(16)c U.S./California 1964–1967 + – – Maternal serum 399
(7) U.S./North Carolina 1978–1982 + + + Maternal serum 872
(8) U.S./Michigan 1980–1981 + + + Maternal serum 196
(9) Netherlands/2 cities 1990–1992 + + + Maternal plasma 415
(10) U.S./New York 1991–1994 – + + Milk 50
(11) Germany/Düsseldorf 1993–1995 – + + Milk 126
(17)c U.S./Massachusetts 1993–1998 – + + Milk 160
(12) Denmark/Faroe Islands 1994–1995 + + + Maternal serum 173
(18)c Canada/Northern Québec 1995–1998 + + + Maternal plasma 159
aType of specimen in which PCB levels were measured. bNumber of specimens on which reported or estimated PCB levels were based, which is not necessarily the same as the num-
ber of children studied. cReferences for these studies are for initial publications; results for neurodevelopmental outcomes are not yet published.
Table 2. Characteristics of the laboratory and data handling methods among studies of PCBs and neurodevelopment.
Method Number of Method Median 
Reference Extraction Gas chromatograph congeners Recovery of lipid PCB 118/median
number Reference location (phase) Cleanup separation qualitated Percent Adjusteda analysis PCB 153b
(15)c U.S./11 cities Solid Florisil High resolution 11 ~65 No Enzymatic 0.87
(16)c U.S./California Liquid Florisil High resolution 11 66 Yes Enzymatic 0.58
(7) U.S./North Carolina Liquid Florisil Packed column NAd > 90 Yes NDe 0.51
(8) U.S./Michigan Liquid Florisil Packed column NA NK No ND 0.32
(9) Netherlands/2 cities Liquid Florisil High resolution 4 > 95 Nof ND 0.18
(10) U.S./New York Liquid Florisil High resolution 68 77 Yes Gravimetric 0.23
(11) Germany/Düsseldorf Solid–liquid Florisil High resolution 3 85 No Photometric 0.20
(17)c U.S./Massachusetts Liquid Silica gelg High resolution 50 95 No Gravimetric 0.47
(12) Denmark/Faroe Islands Solid Florisil High resolution 28h ~65 No Enzymatic 0.27
(18)c Canada/Northern Québec Liquid Florisil High resolution 14 > 95 No Enzymatic 0.14
Abbreviations: NA, not applicable; ND, not determined; NK, not known. 
aAdjusted refers to whether or not the reported PCB levels had been adjusted for recovery. bRatio of median concentrations; for reference (8) this is a ratio of means; for reference (18)
this is a ratio of geometric means. cReferences for these studies are for initial publications; results for neurodevelopmental outcomes are not yet published. dNot applicable for packed
column method. eSerum lipids not determined. fWhether recovery adjustment was done was not specified in published reports and no further information was available; no adjustment
assumed. gAluminum oxide was also used in the cleanup. hIn reference (11), the original authors calculated the sum of PCBs as 2 × (sum of PCBs 138, 153, and 180). 
The relation between PCB measures obtained
using packed column methods and those
from modern high-resolution (congener-spe-
cific) capillary column gas chromatographic
methods was estimated using results from two
small studies where samples were analyzed
both ways.
The PCBs in the samples from the North
Carolina study (7) were originally quantitated
using a “two-peak” packed column method
(23). Aliquots of the original specimens have
been frozen at –20°C since collection. In
1998, aliquots of milk specimens collected
several days after delivery were selected for 10
subjects. The 10 were chosen to span the
range of PCB levels originally measured.
These specimens were analyzed at the Centers
for Disease Control and Prevention (CDC)
in Atlanta, Georgia, using high-resolution
capillary column gas chromatography–mass
spectroscopy. Results were obtained for 36
specific PCB congeners (24). For the 10 spec-
imens analyzed by both methods, the ratio of
the sum of 36 congeners quantitated by the
CDC to the value obtained by the original
“two-peak” method had a median of 0.38
(range, 0.20–0.82); the Pearson correlation
coefficient for the sum of quantitated PCB
levels measured by the two methods was
0.95. Based on the CDC results, the ratio of
the concentration of PCB 153 to the sum of
36 congeners for the 10 specimens had 
a median of 0.17 (range, 0.14–0.21).
Therefore, to reexpress the “two-peak” results
for the North Carolina study in terms of the
values that would have been obtained by
high-resolution methods, we multiplied the
original values by 0.38. Similarly, estimates of
the amounts of PCB 153 were obtained by
further multiplying the estimated sum of
PCB values by 0.17.
PCBs in the samples from the Michigan
study (8,25) were originally quantitated using
a packed column method based on eight
chromatographic peaks. The same method
was used a few years later on blood samples
obtained from the same children at 4 years of
age, and a subset of blood from the 4-year-
olds was also analyzed by a high-resolution
method (26). Two serum pools were created:
one composed of aliquots of equal volume
from 11 female 4-year-olds, and a second
composed of the same for nine male 4-year-
olds. Both pools were analyzed by the same
high-resolution method and the levels of
more than 14 specific congeners were quanti-
fied. The results were compared with the
mean PCB level quantitated by the packed
column method among the subjects in each
pool. For the two pooled specimens, the ratio
of the sum of PCBs obtained by the high-res-
olution method to the value obtained by the
packed column method had a median of 1.1.
In addition, the congener-specific results
showed that the ratio of the concentration of
PCB 153 to the sum of PCBs for the two
specimens had a median of 0.18. Therefore,
to reexpress the original packed column
results for the Michigan study in terms of the
values that would have been obtained by
high-resolution methods, we took the original
values and multiplied them by 1.1, and fur-
ther multiplied them by 0.18 to estimate lev-
els of PCB 153.
Because PCBs are lipophilic, their levels
are often expressed per gram of lipid in the
tissue examined. We reexpressed the wet-
weight PCB levels (µg/L serum) reported in
three studies (7–9) as levels per gram of
serum lipid. For the first two studies, we
assumed that the third-trimester serum lipid
levels were 7.9 g/L, the median of the median
serum lipid levels among the five studies in
which serum lipids were measured (27). For
the third study, the serum cholesterol and
triglyceride values were measured among half
the subjects (data not shown). We assumed
that the median serum lipid level in the
Dutch subjects with lipid measures (8.4 g/L),
estimated using Phillips et al.’s equation (27),
was the same as for those without a lipid mea-
sure. We used the estimated median lipid
level among those with a measure to reexpress
the wet-weight PCB levels for all the Dutch
subjects as levels per gram of serum lipid.
Three studies had milk but not serum
PCB measures available. To reexpress milk
PCB levels (ng/g lipid) as maternal serum
PCB levels (ng/g lipid), we first identified
other studies with “simultaneous” measures of
both. Most had been published (24,28,29),
but for two studies (Québec, Faroes) unpub-
lished data were used. Based on the 14% drop
in median milk PCB levels (fat basis) from
birth to 6 weeks later, observed by Rogan et
al. (28), we assumed that milk PCB levels
decreased by 5% in the first 2 weeks after
birth, and therefore multiplied the Dutch
milk values (collected 2 weeks after birth) by
1.05 so that they would represent the levels at
birth, as in the other studies. The ratio of the
median PCB concentration (lipid basis) in
milk to serum in the five studies (0.79, 1.31,
1.34, 1.59, 1.77) had an unweighted median
value of 1.34. Published correlations between
milk and serum PCB levels were 0.64 (28),
and depending on the congener considered,
0.70–0.79 (29) and 0.62–0.99 (median,
0.90) (18).
The percentage of PCB recovered by the
analytical procedures varied across studies
(Table 2). Most studies either had high
recovery or results adjusted for recovery. The
two studies that used solid-phase extraction
exclusively (12,15) had lower recoveries, and
the reported PCB values were not recovery
adjusted. To make these values more compa-
rable with levels from other studies, we
multiplied the reported values by 1/0.60 for
PCB 153 and 1/0.67 for PCB 118 (30).
Additional information on the effect of
PCB quantitation methods. Our reexpression
of packed column results as high-resolution
results was based on data from a limited
number of specimens analyzed by both meth-
ods. To assess the reasonableness of the con-
version factors used, we also considered
additional data that bear on this issue.
First, we estimated the relation between
the PCB levels as quantitated by the original
packed column methods (7,8). Thus, for 24
specimens from the North Carolina study (7)
that had been quantitated using the “two-
peak” method (22), the original laboratory
results (chromatograms and corresponding
computer printouts) were reviewed by an
analytical chemist (M.S.W.), and the results
were quantitatively reexpressed using the
“eight-peak” method used in the Michigan
study (8). Ordinary least squares regression
showed that PCB levels obtained using the
“two-peak” method gave results that were 2-
fold higher than those obtained using the
“eight-peak” method (Pearson r = 0.98). This
factor-of-two difference between the two
approaches has been confirmed indepen-
dently by Jensen (31). Because the factor to
convert the “two-peak” results to high-resolu-
tion results was 0.38, and for the “eight-peak”
results was 1.1, the ratio we obtained based
on our small number of analyses was
1.1/0.38, or 2.9. With the expected value
being 2, we have some indication of the
potential degree of error in our conversions.
The ratio of PCB concentrations mea-
sured by high-resolution compared with
packed column methods has been examined
by various investigators, who have reported
values ranging from 0.5 to 1.0, with most
ratios being less than 1.0 (32). These ratios
are based on typical packed column methods,
which use about eight peaks in quantitation.
Thus, the ratio of 1.1 for the Michigan data
is consistent with at least some reported val-
ues, even if slightly higher. If the North
Carolina study had used an eight-peak
method of quantitation, the conversion factor
for their study (high resolution to packed col-
umn) would be 0.38 × 2, or 0.76, which is
also consistent with the reported values.
Results
The median concentration of PCB 153 in the
10 studies ranged from 30 to 450 ng/g serum
lipid (Table 3; Figure 1), and the unweighted
median level across the 10 studies (“overall
median”) was 110 ng/g. The median PCB
153 level in the Faroe Islands was 4-fold
greater than the overall median. The median
PCB 153 levels in Massachusetts and New
York, the most recent U.S. studies, were about
one-quarter and one-third of the overall
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median, respectively. Median levels of PCB
153 in the Dutch, German, and Québec stud-
ies were similar to those in the earlier U.S.
studies. Within individual studies, the ratio of
the 95th to the 5th percentiles of PCB 153
concentration ranged from 3.8 (California) to
12.3 (Québec), with a median of 7.5.
One set of assumptions that we made in
our calculations pertained to the factors used
to reexpress packed column results in terms
of what would have been obtained if high-res-
olution methods had been used. As noted
above, conversion factors of 0.5 and 1.0 have
been reported in the literature (32), which
pertain to packed column results based on
about seven or eight peaks. Had we used
these factors to reexpress the North Carolina
data and accounted for the fewer peaks used
in North Carolina, the estimated median
concentration of PCB 153 would have been
50 and 100 ng/g, respectively (instead of 80
ng/g). The former value is just above that
estimated for the New York study; the latter
is the same as that reported for the Québec
study. Recalculation of the Michigan results
using a conversion factor of 0.5 instead of 1.1
gives a median PCB 153 level of 50 ng/g,
which again is just above that estimated for
the New York study.
Along similar lines, the reexpression of
packed column results was influenced by our
choice of the proportion of quantitated PCBs
composed of PCB 153. Among those studies
that based their calculation of the sum of
quantitated PCBs on the sum of more than
four congeners measured by high-resolution
methods, the median proportion PCB 153
was 0.22 (range, 0.18–0.34), compared with
the values of 0.17 and 0.18 used for the
North Carolina and Michigan studies, respec-
tively. Recalculation of the results for the lat-
ter two studies, using the median and highest
reported proportions, yielded median PCB
153 levels of 0.10 and 0.15 for North
Carolina and 0.15 and 0.22 for Michigan.
Among the five studies for which we had
data on the ratio of PCBs in milk to serum,
the median was 1.34 (range, 0.79–1.77). Our
estimated serum PCB 153 levels in New
York, Massachusetts, and Germany depended
on this ratio, so we recalculated the estimated
levels for these three studies using the lowest
and highest reported ratios. The median val-
ues obtained (ng/g lipid) were 70 and 30 for
New York, 50 and 20 for Massachusetts, and
230 and 100 for Germany.
Another assumption was that the concen-
tration of serum lipids was 7.9 g/L. This
assumption affected results for North Carolina
and Michigan. Among the five studies in
which serum lipids were measured, the median
was 7.9 g/L (range, 7.3–8.9). We examined
the effect of using either 7.3 g/L or 8.9 g/L as
the lipid level in each of these two studies; the
impact on the results was negligible.
We assumed a recovery of 0.60 for PCB
153 to estimate levels for the U.S./11 cities
study (15) and the Faroe Islands study (18).
The average recoveries for the four major
congeners in that laboratory ranged from
0.60 to 0.72, a 12% span. We used this span
to inform our choice of alternate recovery val-
ues to use in our sensitivity analyses. Thus,
instead of 0.60, we redid the calculations
using recovery proportions of 0.55 and 0.65
(reflecting a 10% span); the resulting median
PCB 153 values were not substantially differ-
ent from the values presented in Figure 1
(0.16 and 0.13 for the U.S. study and 0.49
and 0.42 for the Faroes study). Recovery rates
in Michigan were not available; if they were
lower than 1.0, the PCB levels could have
been slightly higher than shown in Figure 1.
The ratio of median PCB 118 to median
PCB 153 concentration ranged from 0.14 in
the northern Québec study to 0.87 in the
U.S./11 cities study (Table 2), reflecting some
variation in the relative amounts of congeners
present in the different populations, places,
and times studied. We used these ratios, in
combination with the estimated median PCB
153 levels (Table 3), to estimate the median
concentration of PCB 118 in each popula-
tion. PCB 118 levels were similar across stud-
ies, although levels were higher in the Faroes
(as before) and were relatively higher in the
three earliest studies (data not shown).
Discussion
The primary findings based on the reported
or estimated level of PCB 153 were that a)
the distribution of exposure in the majority of
studies overlapped substantially, b) exposure
levels in the Faroe Islands study was about
3–4-fold higher than in most other studies,
and c) the exposure levels in the more recent
U.S. studies were one-third or more lower
than in the earlier U.S. studies or more recent
European and northern Québec studies.
The coefficient of variation (CV) for the
10 median PCB 153 levels was 88%. In
recent interlaboratory comparisons done by
investigators in Germany, with specimens
from the same serum pool analyzed by
different laboratories using high-resolution
methods, the among-laboratory CV for PCB
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Table 3. Median PCB 153 serum levels among 10 studies of PCBs and neurodevelopment.
Reference Location of Years specimens Median
number population collected (ng/g lipid)
(15)a U.S./11 cities 1959–1965 140
(16)a U.S./California 1964–1967 130
(7) U.S./North Carolina 1978–1982 80
(8) U.S./Michigan 1980–1981 120
(9) Netherlands/2 cities 1990–1992 100
(10) U.S./New York 1991–1994 40
(11) Germany/Düsseldorf 1993–1995 140
(17)a U.S./Massachusetts 1993–1998 30
(12) Denmark/Faroe Islands 1994–1995 450
(18)a Canada/Northern Québec 1995–1998 100
PCB 153 serum levels were estimated in some instances (see “Methods”). 
aReferences for these studies are for initial publications; results for neurodevelopmental outcomes are not yet published.
10 25 50 100 200 400 800 1,600 3,200
ng/g Serum lipid
United States/ 11 cities (1959–1965)
United States/ California (1964–1967)
United States/ North Carolina (1978–1982)
United States/ Michigan (1980–1981)
Netherlands/ 2 cities (1990–1992)
United States/ New York (1991–1994)
Germany/ Düsseldorf (1993–1995)
United States/ Massachusetts (1993–1998)
Denmark/ Faroe Islands (1994–1995)
Canada/ Northern Québec (1995–1998)
Figure 1. Percentiles of the distribution of PCB 153 concentration in serum (5th, 25th, 50th, 75th, and 95th),
obtained using methods to express levels in a uniform manner. Data from 10 studies of neurodevelopment
in humans.
153 at environmental levels (130 ng/g lipid)
was 23% (n = 27 laboratories) and, in another
assessment, was 44% at 190 ng/g lipid (n = 29
laboratories) (33). In a similar comparison
recently done by investigators in the United
States, the among-laboratory CV for PCB 153
(250 ng/g lipid) was 12% (n = 6 laboratories)
(34,35). Thus, the CV among our 10 studies
exceeded that expected because of interlabora-
tory differences, supporting the idea that the
exposure levels in the Faroe Islands and the
two recent U.S. studies were truly different
from the others. If we exclude those three stud-
ies and calculate the CV among the remaining
seven studies, it is 20%. The similarity of the
seven-study CV with that of the among-labo-
ratory CVs suggests that the observed spread in
median PCB levels among the seven studies
could be due entirely to differences from
minor variation in laboratory results, although
there is no reason to reject true differences in
exposure across populations.
The sensitivity analyses gave some indica-
tion of the level of uncertainty about the
results. The assumptions with the largest
potential effect on the findings for which we
have the least confidence were those regarding
a) reexpression of packed column results as
high-resolution results and b) the conversion
of milk to serum PCB levels. The sensitivity
analysis suggests that imprecision introduced
by these assumptions, however, would proba-
bly not alter our primary findings. We note
that in the Dutch study (9), for most major
PCBs, the ratio of levels in milk and serum
was similar to that for PCB 153, suggesting
that use of the milk:serum ratio for PCB 153
instead of the sum of quantitated PCBs would
not have had an important effect on our find-
ings. We chose not to consider the effect of
detection limits being different across studies,
because the median levels of PCB 153 (or for
the sum of quantitated PCBs in the case of
North Carolina or Michigan) were well above
such limits in all studies. The precision of the
lower 5% bounds of the study-specific distrib-
utions of PCB 153 could have been affected
by the detection limits and by the investiga-
tors’ decisions on how to handle values below
those limits.
We chose to examine PCB levels expressed
on a per-unit-serum-lipid basis, to account for
the effect of variation in serum lipid concen-
trations. Although accounting for lipid levels
is sensible, roughly half of serum PCBs are
associated with albumin and other proteins
that are not lipoproteins (36,37). Whether
albumin levels vary substantially among preg-
nant women from different populations is not
clear, although it seems likely that variations
in lipid concentration would be a greater
source of variation in PCBs. We also note that
imprecision of the gravimetric assay for milk
lipids could contribute to the wide variation
in the ratio of milk to serum levels of PCBs,
although direct comparisons of enzymatic and
gravimetric lipid measures have shown a high
level of agreement (38,39).
The use of PCB 153 to assess relative levels
of exposure across populations has many
strengths, such as nearly always being the
largest individual component of the total,
being fairly well resolved from most coeluting
compounds, and being very long-lived in the
body. Yet use of PCB 153 to compare expo-
sures among various epidemiologic studies has
potential limitations. Although PCB 153 con-
stitutes a major fraction of the total PCBs in
humans, its proportion may vary as the source
or type of PCB exposure varies across different
populations. A detailed assessment of the varia-
tion in congener proportions in the 10 studies
considered is beyond the scope of the present
report. In addition, different sets of congeners
were quantitated in each study, further compli-
cating a meaningful comparison of PCB pat-
terns across studies. Besides PCB 153, PCBs
118, 138, and 180 are the major congeners
present and are also usually quantitated. The
ratio of median PCB 118 level to median PCB
153 level varies more than for the correspond-
ing ratios for 138 to 153 or for 180 to 153
(7–9,12,15,17,18,20–22,40,41). This is con-
sistent with the possible greater ease of elimi-
nation of the pentachlorobiphenyl PCB 118
compared with the hexachlorobiphenyls PCBs
138 and 153 and the heptachlorobiphenyl
PCB 180. When we examined PCB 118 levels
across studies (calculated using the 118:153
ratio) to assess the robustness of the 153-based
comparison, the results suggested that the 153-
based comparison (or any comparison based
on the major congeners) works best for those
studies that have greater uniformity in the
mixture of major congeners present [e.g.,
(9,10,11,12,18) but not (15)]. The high corre-
lation among levels of the major specific PCB
congeners within subjects in any given back-
ground-exposed study population has been
well documented (20–22,42). If the concen-
tration of PCB congeners responsible for toxic-
ity is proportional to that of PCB 153, the
latter is likely to give a useful indication of the
relative exposure level across studies.
The data on PCBs and neurodevelop-
ment are not yet published for 4 of the 10
studies included here. Our results are an
important first step toward making interpre-
tation of existing and new data on PCB expo-
sure in relation to neurodevelopment more
straightforward.
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